Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD2018-01-17T17:06:54-05:00
Natalizumab for Relapsing Multiple Sclerosis Natalizumab for Relapsing Multiple Sclerosis2018-01-17T17:06:41-05:00
Campath treatment suspended after serious risks found Campath treatment suspended after serious risks found2018-01-17T17:06:34-05:00
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial2018-01-17T17:06:15-05:00
Oral simvastatin treatment in relapsing-remitting multiple sclerosis Oral simvastatin treatment in relapsing-remitting multiple sclerosis2018-01-17T17:06:09-05:00
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy2018-01-17T17:06:09-05:00
